ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

12,717Medicare Part D Prescriptions Filled, Including Refills

Rank: 33 out of 198

$600K Total Retail Price of All Prescriptions

Rank: 43 out of 198

506 Patients Receiving at Least One Drug in Part D
87%Patients 65 Years and Older
25% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 506 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

14% of this provider’s 506 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

1% of this provider’s 11,336 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

27% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$47 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
LEVOTHYROXINE SODIUM 630 543 1 1
AMLODIPINE BESYLATE 468 421 2 4
FUROSEMIDE 468 426 2 5
OMEPRAZOLE 425 340 4 3
WARFARIN SODIUM 421 406 5 7
LISINOPRIL 372 348 6 6
ATORVASTATIN CALCIUM 358 330 7 12
POTASSIUM CHLORIDE 355 298 8 9
METOPROLOL TARTRATE 347 321 9 10
PRAVASTATIN SODIUM 342 331 10 19
HYDROCODONE-ACETAMINOPHEN 300 273 S3 11 8
SIMVASTATIN 290 271 12 2
ALENDRONATE SODIUM 246 242 13 21
METOPROLOL SUCCINATE 231 227 14 11
LOSARTAN POTASSIUM 230 196 15 18
METFORMIN HCL 222 187 16 13
HYDROCHLOROTHIAZIDE 148 148 17 16
ALLOPURINOL 146 146 18 23
TAMSULOSIN HCL 137 125 19 27
SERTRALINE HCL 118 118 20 25
PREDNISONE 116 90 21 29
DIOVAN 112 112 22 34
LOSARTAN-HYDROCHLOROTHIAZIDE 108 94 23 49
CLOPIDOGREL 107 107 24 42
ISOSORBIDE MONONITRATE ER 100 100 25 60
FAMOTIDINE 100 92 25 57
LANTUS 95 90 27 46
LISINOPRIL-HYDROCHLOROTHIAZIDE 94 83 28 38
ATENOLOL 91 85 29 17
CYMBALTA 90 81 30 48
ZOLPIDEM TARTRATE 90 88 30 22
AMLODIPINE BESYLATE-BENAZEPRIL 90 85 30 99
GABAPENTIN 81 80 33 14
CITALOPRAM HBR 80 72 34 20
PLAVIX 79 79 35 66
DONEPEZIL HCL 79 79 35 28
SPIRIVA 78 70 37 63
DIGOXIN 78 78 37 43
RANITIDINE HCL 73 57 39 54
ESCITALOPRAM OXALATE 71 64 40 53
CRESTOR 71 70 40 26
FLUOXETINE HCL 69 64 42 78
FENTANYL 68 67 S2 43 73
DILTIAZEM ER 66 55 44 98
TRAMADOL HCL 66 54 44 15
OXYCODONE HCL 66 60 S2 44 112
CELEBREX 65 52 47 59
POLYETHYLENE GLYCOL 3350 61 58 48 41
JANUVIA 59 58 49 86
NAMENDA 54 54 50 33
INSULIN SYRINGE 52 41 51 95
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on March 17, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.